BioSpace News Archive

The global market for protein therapeutics has witnessed a significant rise in application in the treatment of a number of genetic, rare, and life-threatening diseases.

The increasing investments by prominent players on research and development activities and innovations are predicted to accelerate the growth of the global oral proteins and peptides market in the near future.

As per the World Health Organization, approximately 8.2 mn deaths that took place in 2012 were caused due to cancer.

Body Composition Analyzers helps in measuring different compounds present within the body and furnishing of their respective values at the point of analysis.

Bioelectronics is an emerging branch of medical science dealing with combined application of the principles of biology and electrical engineering.

Angion Biomedica Corp, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced its management team will participate in a fireside chat with Stifel Managing Director and Senior Analyst Annabel Samimy at the Stifel 2021 Virtual Healthcare Conference.

iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, announces that it will present preclinical data on its next generation autotaxin inhibitor, IOA-289, at the Society for Immunotherapy of Cancer Annual Meeting taking place on November 10–14, 2021 in Washington, D.C. and virtually.

Hyloris Pharmaceuticals SA announces that the first patient has been enrolled in the Phase 2 dose-finding study of Miconazole-Domiphen Bromide, a novel dual-mode-of-action vaginal cream for the treatment of recurring vulvovaginal candidiasis that is being developed in partnership with Purna Female Health.

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce the appointments of Berenberg as its Nominated Adviser and Joint Broker and Jefferies as its Joint Broker with immediate effect.

Calliditas Therapeutics AB publishes the nomination committee’s composition for the AGM in 2022.